A Phase 2 interventional study of Febuxostat and Allopurinol in Hyperuricosuria and Kidney Stones, sponsored by Takeda. Completed at 28 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-02-15.
Sponsored by Takeda · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.
Among the 193 studies in Kidney Calculi with a site in United States, this one is the 44th largest by enrollment of the 165 interventional ones that give a count, is one of 5 that started in 2010, is one of 16 in phase 2, and was the 29th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:
Calyxo, Inc. · Sites in United States
Ages 18+
YolTech Therapeutics Co., Ltd · Sites in United States
Ages 6+
Children's Hospital of Philadelphia · Sites in United States
Ages 6+
Ohio State University · Sites in United States
Ages 18+
Calyxo, Inc. · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
193 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 23 · Phase 3 9 · Phase 4 13
First in 1998; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 47 across the 165 interventional studies, 122 across the 28 observational. Of the 116 that completed or were terminated, 51 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 193 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
Takeda has 1 study filed under Kidney Calculi — fewer than ten, so there is no comparison to draw.
17 of the studies in Kidney Calculi with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07296835University of Kansas Medical CenterSurgical Outcomes and Costs in Using the Shenzhen HugeMed 6.3 French Flexible Ureteroscope | 2026-11 |
| NCT04651088University of Texas Southwestern Medical CenterComparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet | 2026-12 |
| NCT05993546The Cleveland ClinicRandomized Controlled Trial of Miniaturized Percutaneous Nephrolithotomy With Vacuum-Assisted Access Sheaths Versus Conventional Sheaths for Treatment of Nephrolithiasis | 2026-12 |
| NCT04333745University of Alabama at BirminghamInfluence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers | 2026-12-01 |
| NCT04603898University of Alabama at BirminghamOxalate Formation From Ascorbic Acid | 2026-12-01 |
Add all 17 to your calendar (.ics) → With an account.
Among the 193 studies in Kidney Calculi with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the efficacy of febuxostat, once daily (QD), compared to allopurinol or placebo in patients with excessive amounts of uric acid in their urine and who have recently had kidney stones.
Nephrolithiasis, also called kidney stone disease, occurs in patients with genetic susceptibility and who may have a broad spectrum of metabolic disorders and other comorbid conditions (for example obesity or diabetes). These renal stones develop as a result of supersaturation. Calcium oxalate (CaOx) is the most common type of stone. Reducing the urinary excretion of uric acid is an established approach for the treatment of CaOx kidney stones.
The objective of this study is to evaluate treatment with febuxostat compared to allopurinol or placebo in the reduction of 24-hour urine uric acid (uUA) excretion levels in hyperuricosuric patients with a recent history of renal stones and the presence of at least one CaOx stone larger than or equal to 3 mm as seen on Multidetector Computed Tomographic Angiography (MDCT).
Participants in this study will be required to make 4 office visits provide 3 urine samples and undergo 2 MDCT scans (a type of x-ray) of their kidneys.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Has hypercalciuria at Screening, while on a regular unrestricted diet, defined as urinary excretion of:
EXCLUDED MEDICATIONS:
The following restrictions also apply during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
Drug: Febuxostat
Allopurinol 200mg or 300mg (determined by kidney function), capsules, orally, once daily for up to 6 months.
Drug: Allopurinol
Placebo-matching capsules, orally, once daily for up to 6 months.
Drug: Placebo
Febuxostat capsules
Also known as: Uloric, TMX-67
Allopurinol capsules
Also known as: Zyloprim
Placebo-matching capsules
Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion
The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.
Time frame: Baseline and Month 6
Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone
Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader. The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.
Time frame: Baseline and Month 6
Change From Baseline to Month 6 in the Number of Calcium Oxalate Stones
Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader.
Time frame: Baseline and Month 6
Change From Baseline to Month 6 in 24-hour Measured Creatinine Clearance
Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles. Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).
Time frame: Baseline and Month 6
Participants took part in the study at 24 investigative sites in the United States from 12 February 2010 to 21 November 2011.
| Milestone | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Started | 33 | 33 | 33 |
| Completed | 28 | 28 | 30 |
| Not completed | 5 | 5 | 3 |
| Withdrew: Adverse event | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 1 | 2 | 0 |
| Withdrew: Withdrawal by subject | 2 | 3 | 1 |
| Withdrew: Other | 0 | 0 | 1 |
The change from Baseline to Month 6 in 24-hour urine uric acid is expressed as a percentage of the Baseline uUA value.
| percent change | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Percent Change From Baseline to Month 6 in 24-hour Urine Uric Acid (uUA) Excretion | -58.6 ± 28.56 | -36.4 ± 36.97 | -12.7 ± 28.81 |
Multidetector Computed Tomography (MDCT) was used to visualize and measure calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader. The change from Baseline to month 6 is expressed as a percentage of the Baseline largest in-plane diameter.
| percent change | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Percent Change From Baseline to Month 6 in the In-plane Diameter of the Largest Calcium Oxalate (CaOx) Stone | -6.50 ± 28.357 | 0.63 ± 12.605 | 3.20 ± 23.697 |
Multidetector Computed Tomography (MDCT) was used to visualize and count calcium oxalate kidney stones at Baseline and after 6 months of treatment. All MDCT images were analyzed independently by a Central Reader.
| stones | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Baseline (n=28, 24, 30) | 4.84 ± 3.921 | 6.60 ± 6.832 | 5.57 ± 5.785 |
| Change from Baseline (n=26, 23, 26) | -0.06 ± 1.602 | 0.28 ± 1.953 | 0.10 ± 1.817 |
Creatinine clearance is a measure of how well the kidneys are filtering creatinine, a waste product produced by the muscles. Measured creatinine clearance was calculated according to the following: Urine 24 hour Creatinine/Serum Creatinine x (total Urine volume/elapsed time) x (1.73/body surface area).
| mL/min/1.73m² | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Baseline (n=33, 33, 33) | 146.9 ± 57.88 | 146.0 ± 44.32 | 147.1 ± 53.46 |
| Change from Baseline (n=30, 29, 30) | -9.0 ± 60.82 | -7.7 ± 83.28 | -19.0 ± 45.72 |
Collected over Treatment emergent AEs were defined as any AE, regardless of relationship to study drug, which occurred on or after the first double blind dose date and up to 30 days after the last dose date of the double-blind study drug (up to 7 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Febuxostat | — | 0/33 (0%) | 14/33 (42.4%) |
| Allopurinol | — | 0/33 (0%) | 13/33 (39.4%) |
| Placebo | — | 1/33 (3%) | 12/33 (36.4%) |
| Event | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| NephrolithiasisRenal and urinary disorders | 0/33 | 0/33 | 1/33 |
| Event | Febuxostat | Allopurinol | Placebo |
|---|---|---|---|
| Flank painMusculoskeletal and connective tissue disorders | 4/33 | 0/33 | 2/33 |
| Back painMusculoskeletal and connective tissue disorders | 1/33 | 3/33 | 1/33 |
| Upper respiratory tract infectionInfections and infestations | 0/33 | 2/33 | 3/33 |
| NephrolithiasisRenal and urinary disorders | 3/33 | 1/33 | 3/33 |
| HeadacheNervous system disorders | 0/33 | 3/33 | 3/33 |
| Oedema peripheralGeneral disorders | 1/33 | 3/33 | 1/33 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/33 | 2/33 | 0/33 |
| Blood creatine phosphokinase increasedInvestigations | 2/33 | 0/33 | 0/33 |
| Creatinine urine increasedInvestigations | 2/33 | 0/33 | 0/33 |
| Urine calcium increasedInvestigations | 2/33 | 1/33 | 0/33 |
| Age Continuous(years) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Mean | 49.1 ± 9.69 | 46.5 ± 9.95 | 46.5 ± 11.54 | 47.4 ± 10.39 |
| Sex: Female, Male(Participants) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Female | 6 | 2 | 6 | 14 |
| Male | 27 | 31 | 27 | 85 |
| Race/Ethnicity, Customized(participants) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 8 | 8 | 3 | 19 |
| Non-Hispanic and Latino | 25 | 25 | 30 | 80 |
| Race/Ethnicity, Customized(participants) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Asian | 2 | 0 | 2 | 4 |
| Black or African American | 3 | 1 | 1 | 5 |
| Native Hawaiian or other Pacific Islander | 1 | 0 | 1 | 2 |
| White | 26 | 31 | 29 | 86 |
| Other | 1 | 1 | 0 | 2 |
| Region of Enrollment(participants) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| United States | 33 | 33 | 33 | 99 |
| Height(cm) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Mean | 172.6 ± 12.67 | 176.5 ± 7.71 | 174.3 ± 9.31 | 174.5 ± 10.14 |
| Weight(kg) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Mean | 98.0 ± 18.17 | 100.9 ± 20.13 | 100.8 ± 20.23 | 99.9 ± 19.38 |
| Body mass index (BMI)(kg/m^2) | Febuxostat | Allopurinol | Placebo | Total |
|---|---|---|---|---|
| Mean | 32.9 ± 5.71 | 32.3 ± 5.82 | 33.1 ± 6.29 | 32.8 ± 5.89 |
13 further baseline measures are reported on the registry.
The record gives a start of Feb 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2013, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Febuxostat